EA201992346A1 - REPLACEMENT OF CYTOTOXIC PRELIMINARY CONDITIONING BEFORE CELLULAR IMMUNOTHERAPY - Google Patents

REPLACEMENT OF CYTOTOXIC PRELIMINARY CONDITIONING BEFORE CELLULAR IMMUNOTHERAPY

Info

Publication number
EA201992346A1
EA201992346A1 EA201992346A EA201992346A EA201992346A1 EA 201992346 A1 EA201992346 A1 EA 201992346A1 EA 201992346 A EA201992346 A EA 201992346A EA 201992346 A EA201992346 A EA 201992346A EA 201992346 A1 EA201992346 A1 EA 201992346A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cytotoxic
replacement
cellular immunotherapy
conditioning before
preliminary conditioning
Prior art date
Application number
EA201992346A
Other languages
Russian (ru)
Inventor
Тереза Энн Деишер
Original Assignee
Авм Байотекнолоджи, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авм Байотекнолоджи, Ллс filed Critical Авм Байотекнолоджи, Ллс
Priority claimed from PCT/US2018/025517 external-priority patent/WO2018183927A1/en
Publication of EA201992346A1 publication Critical patent/EA201992346A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В данном документе представлены новые терапевтические композиции и способы, которые сохраняют клеточную иммунотерапию в кровотоке или в участке инъекции в течение длительных периодов времени, не прибегая к применению цитотоксического предварительного кондиционирования. Более конкретно, композиции и способы, описанные в данном документе, лимфодеплетируют и уменьшают или удаляют участки во вторичных лимфоидных органах, где клеточная иммунотерапия связывается и секвестрируется, без применения цитотоксического предварительного кондиционирования.This document presents new therapeutic compositions and methods that retain cell immunotherapy in the bloodstream or at the injection site for extended periods of time without resorting to cytotoxic preconditioning. More specifically, the compositions and methods described herein lymphodeplet and reduce or remove sites in the secondary lymphoid organs where cell immunotherapy binds and sequestrates without cytotoxic preconditioning.

EA201992346A 2018-01-31 2018-03-30 REPLACEMENT OF CYTOTOXIC PRELIMINARY CONDITIONING BEFORE CELLULAR IMMUNOTHERAPY EA201992346A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624454P 2018-01-31 2018-01-31
PCT/US2018/025517 WO2018183927A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Publications (1)

Publication Number Publication Date
EA201992346A1 true EA201992346A1 (en) 2020-03-18

Family

ID=69942850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992346A EA201992346A1 (en) 2018-01-31 2018-03-30 REPLACEMENT OF CYTOTOXIC PRELIMINARY CONDITIONING BEFORE CELLULAR IMMUNOTHERAPY

Country Status (1)

Country Link
EA (1) EA201992346A1 (en)

Similar Documents

Publication Publication Date Title
MX2019011679A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy.
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
EA202092590A1 (en) PYRIDAZINONES AS PARP7 INHIBITORS
MX2019008208A (en) Methods of treating cancer with anti-tim-3 antibodies.
JOP20200300A1 (en) Il-11ra antibodies
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201692530A1 (en) CYTOTOXIC PEPTIDES AND THEIR CONJUGATES
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022007968A (en) Gamma-hydroxybutyrate (ghb) dosing.
CR20210622A (en) Multispecific heavy chain antibodies binding to cd22 and cd3
EA202191122A1 (en) SELECTIVE TO RGMc INHIBITORS AND THEIR APPLICATION
EA202091557A1 (en) ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND CD22
MX2021004732A (en) Heavy chain antibodies binding to cd38.
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
EA201791807A1 (en) NEW TRITERPENON WITH C-3 WITH REVERSE AMIDIC DERIVATIVES WITH C-17 AS HIV INHIBITORS
CR20220216A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EA202090270A1 (en) NEW SUBSTITUTED Xanthine Derivatives
MX2020011027A (en) Trivalent trispecific antibody constructs.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
CR20230525A (en) Anti-cd20 antibodies and car-t structures
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202191403A1 (en) COMPOSITION WITH HIGH PROTEIN CONCENTRATION
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION